TORONTO and HAIFA, Israel, March 01, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Affairs at NurExone, will be leading a workshop at the

innovations and know-how in exosome production suited for many clinical applications TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation

TORONTO and HAIFA, Israel, Feb. 02, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), known as “NurExone,” is pleased to announce the initiation of the Orphan Drug Designation process with the European Medicines Agency (EMA) for its groundbreaking ExoPTEN product, currently in development for patients with

TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to share several updates. The collaborative agreement between NurExone and Inteligex Inc.

TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that it has closed a non-brokered private placement (the

In the latest development, NurExone has developed two selective small inhibiting RNA sequences (siRNA) that target and inhibit proteins within the Peri-Neural Network (PNN) complex (Fig. 1A). The breakthrough sequences, detailed in a patent application held by the Company, are built upon a scientifically validated strategy for enhanced neuronal regeneration

“I am pleased to report that we have reached a new pivotal point for our proprietary ExoPTEN drug, primarily in advancing our United States Food and Drug Administration regulatory strategy and the commercialization of our exosome-based technology portfolio,” said Dr. Lior Shaltiel, CEO of NurExone.   Read More >>>